Key result
TAVR in ESRD carries ~89% five-year mortality despite improving short-term survival.
Why the study?
Although aortic stenosis is prevalent in end-stage renal disease and TAVR is a plausible alternative to surgical aortic valve replacement, little is known regarding long-term outcomes after TAVR in these patients.
What are the long-term mortality outcomes and associated risk factors in patients with end-stage renal disease undergoing transcatheter aortic valve replacement?
Population
3883 TAVR procedures in patients with end-stage renal disease
Design
Retrospective registry-based cohort study
Follow-up
5 years
Authors
Loading...
High 5-year mortality in ESRD patients after TAVR warrants cautious selection; leaves open need for prospective outcome studies.
Cohort (n=3,883)
Yes
What are the long-term mortality outcomes and associated risk factors in patients with end-stage renal disease undergoing transcatheter aortic valve replacement?
While short-term mortality after TAVR in patients with end-stage renal disease has significantly improved over time, long-term (5-year) mortality remains extremely high at nearly 89%.
Ogami et al. (2021) conducted a cohort in Aortic stenosis in end-stage renal disease (n=3,883). Transcatheter aortic valve replacement (TAVR) was evaluated on 5-year mortality after TAVR. In patients with end-stage renal disease undergoing TAVR, 5-year mortality was 88.8%, though 30-day mortality decreased significantly from 11.1% in 2012 to 2.5% in 2016 (P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: